A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5)
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 600
- Started
- 3 December 2025
- Main results due (estimated)
- 18 June 2029
- Study ends (estimated)
- 18 July 2029
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- None
- Sites
- 205 · 6 in India
- First posted
- 11 December 2025
- Registry updated
- 3 November 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion criteria: * Be more than or equal to (\>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater) * Have histologically or cytologically confirmed recurrent/metastatic (R/M) HNSCC that is considered incurable by local therapies: a. eligible primary tumor locations are the oral cavity, oropharynx, hypopharynx, or larynx; b. Must not have a primary tumor site of nasopharynx or primary tumor of unknown location; c. Must have documented local testing results per local regulations; d. Human papillomavirus (HPV) status must be known for participants with primary tumor location in oropharynx via p16 test, HPV DNA test, or high-risk HPV in situ hybridization (ISH). Any known p16, HPV DNA, or high-risk HPV ISH status of tumor must be negative * Be treatment-naive for systemic therapy in the R/M setting * Have an ECOG performance status of 0 or 1 * Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 Exclusion criteria: * Have an uncontrolled illness * Have untreated brain metastases or history of known presence of leptomeningeal disease * Have a history of clinically significant cardiovascular disease * Inadequate organ or bone marrow function * Known allergies, hypersensitivity, contraindications, or intolerance to excipients of: Amivantamab, Pembrolizumab, Carboplatin, Cisplatin, 5-FU and Hyaluronidase
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
What participants receive
- Experimental
Arm A: Pembrolizumab, Amivantamab, Carboplatin
Participants will receive pembrolizumab, amivantamab and carboplatin.
Biological: Amivantamab · Biological: Pembrolizumab · Drug: Carboplatin
- Active comparator
Arm B: Pembrolizumab, 5-Flurouracil (5-FU), Carboplatin or Cisplatin
Participants will receive pembrolizumab, 5-FU and carboplatin or cisplatin (platinum therapy).
Biological: Pembrolizumab · Drug: Carboplatin · Drug: 5-Flurouracil · Drug: Cisplatin
Interventions
AmivantamabBiological
Also known as JNJ-61186372, RYBREVANT
Amivantamab will be administered.
PembrolizumabBiological
Pembrolizumab will be administered.
CarboplatinDrug
Carboplatin will be administered.
5-FlurouracilDrug
5-Flurouracil will be administered for over 4-day infusion period.
CisplatinDrug
Cisplatin will be administered.
What the study measures
Primary outcomes
Overall Survival (OS)
OS is defined as time from the date of randomization to the date of death due to any cause.
Time frame: Up to approximately 3 years 7 months
Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
ORR is defined as the percentage of randomized participants achieving a confirmed best overall response (BOR) of partial response (PR) or complete response (CR) by BICR using RECIST version 1.1 .
Time frame: Up to approximately 3 years 7 months
Secondary outcomes
Progression-Free Survival (PFS) Using RECIST Version 1.1, as Assessed by BICR
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, based on BICR assessment using RECIST v1.1, regardless of treatment discontinuation or start of subsequent anticancer therapy.
Time frame: Up to approximately 3 years 7 months
Duration of Response (DOR) As Assessed by BICR
DOR as assessed by BICR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as best response.
Time frame: Up to approximately 3 years 7 months
ORR as Assessed by Investigator
ORR as assessed by the investigator is defined as the percentage of randomized participants achieving CR or PR, as defined by investigator assessment using RECIST v1.1 criteria.
Time frame: Up to approximately 3 years 7 months
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy, whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy or any AE that is considered treatment-related regardless of the start date of the event.
Time frame: Up to approximately 3 years 7 months
Number of Participants with Laboratory Abnormalities
Blood samples will be collected to determine the laboratory (serum chemistry and hematology) abnormalities.
Time frame: Up to approximately 3 years 7 months
Percentage of Participants with Improved or Stable Symptoms Compared to Baseline as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module 43 (EORTC QLQ-HN43) Symptom Scale Score
EORTC QLQ-HN43, is a self-administered, 43-item questionnaire measuring the health-related quality of life (HRQoL) of participants with head and neck cancer. EORTC QLQ-HN43 includes 19 scales (anxiety, body image, coughing, dry mouth and sticky saliva, neurological problems, opening mouth, pain in the mouth, social contact, problems with senses, shoulder problems, skin problems, swelling in the neck, social eating, speech, swallowing, sexuality, problems with teeth, weight loss, and problems with wound healing). Responses to items are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Higher scores indicate worse health outcomes.
Time frame: Baseline, up to approximately 3 years 7 months
Percentage of Participants with Improved or Stable Symptoms Compared to Baseline as Measured by EORTC QLQ-Core (C) 30 Symptom Scale Score
EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 3 symptom scales (fatigue, pain, and nausea and vomiting), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.
Time frame: Baseline, up to approximately 3 years 7 months
Change from Baseline in Functioning HRQoL, as Measured by Functioning Scales of the EORTC QLQ-C30
EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.
Time frame: Baseline, up to approximately 3 years 7 months
Change from Baseline in Overall HRQoL, as Measured by Global Health Scales of the EORTC QLQ-C30
EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, or more severe symptoms.
Time frame: Baseline, up to approximately 3 years 7 months
Differences Between Treatment Groups (Arms A and B) for EORTC Quality of Life (QLG) Item Library-46 (IL-46) Tolerability Scale Scores
EORTC IL46 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Higher score indicates more impact of treatment side-effects.
Time frame: Up to approximately 3 years 7 months
Serum Concentration of Amivantamab
Serum concentrations of amivantamab will be analyzed.
Time frame: Up to approximately 3 years 7 months
Number of Participants with Serum Anti-Amivantamab Antibodies
Participants who are positive to serum anti-amivantamab antibodies will be reported.
Time frame: Up to approximately 3 years 7 months
Who is running it
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Janssen Research & Development, LLC
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- 61186372HNC3001
- Other IDs
- 61186372HNC3001, 2025-521917-24-00, 2025
Janssen Research & Development, LLC Clinical Trial
Study director
Janssen Research & Development, LLC
Study sites(205)
Apollo Speciality Hospital, Chennai
Chennai, India
Recruiting
Bhagwan Mahaveer Cancer Hospital & Research Centre
Jaipur, India
Recruiting
Chittaranjan National Cancer Institute (CNCI)
Kolkata, India
Recruiting
HealthCare Global HCG Manavata Cancer Centre
Nashik, India
Recruiting
All India Institute of Medical Sciences
New Delhi, India
Recruiting
Kailash Cancer Hospital and Research Centre
Vadodara, India
Recruiting
Ironwood Cancer and Research Center
Chandler, Arizona, United States
Recruiting
University of Arizona Cancer Center
Tucson, Arizona, United States
Recruiting
Providence St Jude Medical Center
Fullerton, California, United States
Recruiting
Scripps Health
La Jolla, California, United States
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
Recruiting
University of California, Los Angeles UCLA
Los Angeles, California, United States
Recruiting
Valkyrie Clinical Trials Murrieta
Murrieta, California, United States
Recruiting
University Of California - Davis
Sacramento, California, United States
Recruiting
UCSF Medical Center at Mission Bay
San Francisco, California, United States
Recruiting
Stanford University Medical Center
Stanford, California, United States
Recruiting
Hartford Hospital
Hartford, Connecticut, United States
Recruiting
Yale Cancer Center
New Haven, Connecticut, United States
Recruiting
Florida Cancer Specialists South
Fort Myers, Florida, United States
Recruiting
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Recruiting
AdventHealth Medical Group Oncology and Hematology at Orlando
Orlando, Florida, United States
Recruiting
Florida Cancer Specialists North Region
St. Petersburg, Florida, United States
Recruiting
Florida Cancer Specialists East
West Palm Beach, Florida, United States
Recruiting
Emory University
Atlanta, Georgia, United States
Recruiting
Central Georgia Cancer Care
Macon, Georgia, United States
Recruiting
Rush University Medical Center Rush University Cancer Center Chicago
Chicago, Illinois, United States
Recruiting
The University of Chicago Medical Center (UCMC)
Chicago, Illinois, United States
Recruiting
Cancer Care Specialists of Central Illinois
O'Fallon, Illinois, United States
Recruiting
University of Kentucky Medical Center
Lexington, Kentucky, United States
Recruiting
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
Trinity Health St Joseph Mercy Ann Arbor
Ann Arbor, Michigan, United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Washington University School Of Medicine
St Louis, Missouri, United States
Recruiting
NHO Revive Research Institute, LLC
Lincoln, Nebraska, United States
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, United States
Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
Bronx Veterans Affairs Medical Center
The Bronx, New York, United States
Recruiting
Showing 40 of 205 sites. 205 recruiting, 0 not recruiting and 0 cancelled; 6 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Source: ClinicalTrials.gov record NCT07276399, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.